BGPartner advises OrbiMed and Novo Holdings on Series A of Windward Bio to USD 200 mio
10. January 2025
Windward Bio Group Ltd, a Swiss-based private, clinical-stage, drug development company successfully launched with a USD 200 m Series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners.
Windward Bio Group Ltd committed to improving outcomes for people living with advanced immunological diseases. Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with potential in asthma and chronic obstructive pulmonary disease (COPD).
BGPartner advised OrbiMed and Novo Holdings on all Swiss legal matters and the negotiations of this Series A financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate).